CAS NO:112665-43-7  Seratrodast
CAS NO:112665-43-7  Seratrodast
CAS NO:112665-43-7  Seratrodast
CAS NO:112665-43-7  Seratrodast
CAS NO:112665-43-7  Seratrodast
CAS NO:112665-43-7  Seratrodast
+
  • CAS NO:112665-43-7  Seratrodast
  • CAS NO:112665-43-7  Seratrodast
  • CAS NO:112665-43-7  Seratrodast
  • CAS NO:112665-43-7  Seratrodast
  • CAS NO:112665-43-7  Seratrodast
  • CAS NO:112665-43-7  Seratrodast

CAS NO:112665-43-7 Seratrodast

CAS NO:112665-43-7 NAME:Seratrodast MF:C22H26O4 MW:354.44 EINECS:692-169-8 APPEARANCE:Pale Orange to Yellow Solid PURITY:98%+ COA:Available SAMPLE:Negotiable

Categories:

Life Science Chemicals

Pharmaceutical Intermediates

Product introduction

PRODUCT NAME  Seratrodast
CAS NO 112665-43-7  
MP 118-120°C
BP 522.3±49.0 °C(Predicted)
DENSITY 1.140±0.06 g/cm3(Predicted)
STORAGE 2-8°C
DELIVERY 2-3DAYS
PACKAGE According client's request

Description of CAS NO:112665-43-7  Seratrodast

Seratrodast is a thromboxane receptor antagonist that is used to treat asthma. However, this drug does not affect thrombus formation as other thromboxane synthase inhibitors do such as ozagrel.

 

 


Applications of CAS NO:112665-43-7  Seratrodast

1. Asthma Control and Mucociliary Clearance
Seratrodast, a thromboxane A2 receptor antagonist, has been studied for its effects on asthma control and airway secretions.

2. Inhibition of Airway Contraction
3. Anti-Inflammatory Effects in Asthma
4. Modulation of Eosinophil Activation
Seratrodast also shows potential in modulating eosinophil activation. 
5. Inhibiting Hypersecretion in COPD

Future Directions
Recent research has focused on the development of Seratrodast platinum (iv) hybrids, which have shown promise in inhibiting cancer-related thrombosis and metastasis phenotype in vitro and in vivo . Another study found that Seratrodast was better in the improvement of peak expiratory flow, reduction in expectoration, eosinophil cationic protein, and albumin levels as compared to montelukast .

Key words:

Related Products

Related Products

Inquiry

SUBMIT